UK Risks Becoming ‘Economically Unviable’ For Biosimilars
BGMA Report Warns Over VPAS Impact And Calls For National Biosimilars Strategy
Amid increasing financial pressure from the VPAS rebate scheme and a lack of a national uptake strategy, the BGMA has warned that the UK risks losing its leading position in European biosimilars and could become altogether “economically unviable” for biosimilars suppliers.
You may also be interested in...
Proposals published by the UK government as part of a consultation on its statutory scheme for branded medicine pricing have been welcomed by local off-patent industry association the BGMA. The proposals include a “lifecycle adjustment” mechanism to allow a lower rebate rate for medicines being sold in competitive markets.
Claiming that the UK’s VPAS rebate scheme is “out of control,” local generics and biosimilars association the BGMA has set out a series of suggestions to improve the mechanism, as it continues to battle for formal involvement in negotiations with the government.
The UK government’s announcement of a 26.5% VPAS rate for 2023 “will make some products lossmaking,” the BGMA has cautioned, expressing serious concerns for the branded generics and biosimilars sector as it points to the risk of shortages, higher prices and fewer launches in the UK.